ONCY Insider Trading Activity and SEC Form 4 Filings
ONCY insider trading summary
Over the past 12 months, insiders at Oncolytics Biotech Inc (ONCY) reported 12 open-market purchases worth $347K by 9 insiders and no sales on SEC Form 4. Net insider buying was $347K.
Latest ONCY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 12, 2026 | Patricia S Andrews | Director | Buy | $30K (35,400 @ $0.86) |
| Feb 12, 2026 | Wayne Pisano | Director | Buy | $25K (30,000 @ $0.84) |
| Feb 12, 2026 | Allison Hagerman | VP, Product Development | Buy | $8K (10,000 @ $0.83) |
| Feb 12, 2026 | Deborah Margaret Brown | Director | Buy | $21K (25,000 @ $0.85) |
| Feb 12, 2026 | Bernd R. Seizinger | Director | Buy | $34K (40,000 @ $0.85) |
| Feb 12, 2026 | Thomas Charles Heineman | Chief Medical Officer | Buy | $10K (12,132 @ $0.83) |
| Feb 12, 2026 | Jared Kelly | Chief Executive Officer | Buy | $25K (29,500 @ $0.84) |
| Feb 12, 2026 | Kirk Look | Chief Financial Officer | Buy | $10K (12,000 @ $0.84) |
| Feb 11, 2026 | Jared Kelly | Chief Executive Officer | Buy | $5K (5,600 @ $0.84) |
| Feb 11, 2026 | Bernd R. Seizinger | Director | Buy | $50K (60,000 @ $0.83) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.